Organon & Co (OGN) Options Open Interest

Monitoring OGN open interest helps you see where real money is positioned on Organon & Co's options and which strikes are attracting the most commitment from traders. Organon & Co's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor OGN options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising OGN options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Organon & Co to settle.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.

In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where OGN open interest is concentrated. Our scanner maps Organon & Co's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Organon & Co's options open interest as the signal it is, not as an afterthought.